Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Duchenne Community Keeps The Faith After Dual New Product Setback

Executive Summary

The DMD community could be forgiven for feeling disheartened by recent setbacks to potential new treatments in the US and EU. Patient power will not be enough to get DMD drugs past regulators but companies and advocacy groups are keeping the faith. Among other things, they hope that better natural history data may help their cause.

You may also be interested in...



Seven Green Lights From EU’s CHMP, Including Drugs For Hemophilia, Diabetes, Alpha Mannosidosis And Hyperkalemia

The European Medicines Agency’s CHMP has OKd seven new products, including drugs for hemophilia A, diabetes, alpha mannosidosis, hyperkalemia and herpes zoster. But it again rejected Santhera’s filing for Raxone in the new indication of Duchenne muscular dystrophy, and also turned down Repros’ Encyzix for hypogonadism.

Santhera Braced For Another CHMP No In Duchenne

Santhera had a tumultuous 2017 and recovery is not going to be easy this year as its lead compound for the rare disease Duchenne muscular dystrophy is about to be rejected by regulators in Europe for a second time.

Confident Catabasis Takes Positives From Failed Duchenne Trial Into Phase III

The US biotech has presented positive data from a mid-stage trial of edasalonexent that had previously missed its primary endpoint and hopes the goals it has set for Phase III will be enough to satisfy regulators.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS121682

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel